Part of the site of a Vodafone headquarters is going to be turned into a new science park backed by Saudi investors. Oval Real Estate has officially begun the redevelopment of The Connection, a more ...

AbbVie's study also met all secondary goals, with 64.1% patients on Qulipta seeing a 50% or more reduction in the average number of days per month when they experience migraine headaches.

As Souers and his colleagues in AbbVie’s labs work to find more solutions to treat cancer, the company is increasing its awareness campaign for cancer advocacy, including a partnership with the ...

In the latest trading session, AbbVie (ABBV) closed at $186.11, marking a +0.26% move from the previous day. The stock's change was more than the S&P 500's daily loss of 0.01%. Elsewhere, the Dow ...

AbbVie (NYSE:ABBV) experienced a 6.8% share price increase over the past month, coinciding with several significant corporate events. The company announced a collaboration with ADARx ...

AbbVie Raises Full-Year Profit Outlook AbbVie lifted its full-year adjusted EPS profit forecast to a range of $12.09 to $12.29 from the prior $11.99 to $12.19. The company said its current outlook ...

AbbVie is poised to grow this year for the first time since Humira's U.S. patent expired. The dividend yields a generous 3.7% and features decades of consistent growth. While tariffs, politics ...

AbbVie stock outperformed S&P 500 with a +16% to 9.41% return since November 2023, despite Humira revenue declining 38% to $8.99 billion. Immunology drugs Skyrizi and Rinvoq grew over 50% year ...

CHICAGO (CBS) -- University of Chicago Medicine has received a $75 million donation from the nonprofit AbbVie Foundation to help fund the construction of the hospital's new cancer center.

The AbbVie Foundation, a nonprofit dedicated to addressing health inequities, has made a $75 million donation to the University of Chicago to support the construction of UChicago Medicine’s new cancer ...

Pharmaceutical giant AbbVie has sued cancer treatment maker BeiGene in Chicago federal court, accusing it of stealing trade secrets to develop a competing cancer-fighting therapy after hiring away ...

Humira is under pressure, but AbbVie's dividend is still rising. At recent prices, it offers a 3.6% yield that is more than double what you'd receive from the average stock in the S&P 500 index.